Analyse Recursion Pharmaceuticals, Inc. (RXRX) — Kairos Score 56/100

À propos de Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Informations clés

🕴️ Activité des initiés (90 jours)

8 transactions — 0 achats et 4 ventes déclarés par les dirigeants de Recursion Pharmaceuticals, Inc..

🏦 Hedge Funds

26 fonds institutionnels déclarent une position sur RXRX dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur RXRX.

• Has Recursion Pharmaceuticals (RXRX) Fallen Far Enough on Sales?
• Why Recursion Pharmaceuticals Stock Is In Focus After Drug Data And Sanofi Milestone

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.